Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Launched by THE GEORGE WASHINGTON UNIVERSITY BIOSTATISTICS CENTER · Apr 17, 2001
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
The prevalence of cerebral palsy is increasing as the survival rate of extremely premature infants is improving. Studies have suggested an apparent association between maternal magnesium sulfate administration and a reduced risk of cerebral palsy. Other studies have suggested a possible association between magnesium sulfate and a reduction in neonatal cranial ultrasound abnormalities which may be markers for subsequent development of cerebral palsy.
This multicenter trial tests whether prophylactic magnesium sulfate given to women, for whom preterm delivery is imminent, reduces the risk of...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant with diagnosis of preterm labor
- • Membrane rupture or delivery definitely planned within 24 hours
- • Gestational age \> 24.0 and \< 31.6 wks, viable fetus
- Exclusion Criteria:
- • Prior IV magnesium sulfate therapy within 12 hours of screening
- • Delivery expected \<2 hrs
- • Cervical dilation \> 8 cm
- • More than 2 fetuses
- • Known major fetal anomalies
- • Hypertension or preeclampsia
- • Maternal medical complications contraindicating magnesium sulfate treatment
- • Participation in any intervention study which influences infant neurological outcome
- • Previous participation in this trial
About The George Washington University Biostatistics Center
The George Washington University Biostatistics Center is a leading research institution dedicated to advancing the field of biostatistics through innovative methodologies and rigorous scientific inquiry. As a prominent sponsor of clinical trials, the center specializes in the design, analysis, and interpretation of complex data in health-related research. With a commitment to enhancing public health outcomes, the Biostatistics Center collaborates with academic, governmental, and industry partners to foster evidence-based practices and promote the development of effective therapeutic interventions. Through its expertise, the center plays a vital role in ensuring the integrity and reliability of clinical research data, ultimately contributing to informed decision-making in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Chapel Hill, North Carolina, United States
Salt Lake City, Utah, United States
Birmingham, Alabama, United States
Miami, Florida, United States
Detroit, Michigan, United States
New York, New York, United States
Winston Salem, North Carolina, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Providence, Rhode Island, United States
Dallas, Texas, United States
Galveston, Texas, United States
Houston, Texas, United States
Patients applied
Trial Officials
Dwight Rouse, MD
Principal Investigator
University of Alabama at Birmingham
Menachem Miodovnik
Study Director
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials